Skip to main content

Table 2 Treatment characteristics

From: Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol

  

Total group (n = 94)

Study group (n = 18)

Control group (n = 18)

p-values*

  

n

%

value (range)

n

%

value (range)

n

%

value (range)

 

Surgical treatment

Total

88

93.6

 

17

94.4

 

15

83.3

 

(0.279)

 

Local resection

78

83.0

 

14

77.7

 

14

77.7

 

(0.397)

 

Neck dissection

10

10.6

 

3

16.7

 

1

5.6

 

(0.790)

Brachytherapy

Total dose (Gy)

  

25.9 (10–35)

  

27.0 (15–35)

  

27.1 (20–30)

(0.696)

 

Single dose (Gy)

  

2.5 (2.5-4.5)

  

2.5 (2.5-3.0)

  

2.5 (2.5-2.5)

(0.791)

 

Fractions

  

10.2 (4–14)

  

10.6 (6–14)

  

10.8 (8–12)

(0.938)

 

Radiation days

  

6.3 (1–11)

  

7.1 (4–9)

  

6.6 (3–9)

(0.202)

 

V100 (ml)

  

50.0 (3.6-149.5)

  

61.9 (22.3-149.5)

  

46.4 (4.0-111.1)

(0.291)

 

V150 (ml)

  

19.1 (1.6-65.3)

  

23.1 (7.1-55.2)

  

17.0 (2.0-37.3)

(0.347)

 

DNR

  

0.37 (0.32-0.56)

  

0.35 (0.28-0.46)

  

0.40 (0.29-0.56)

(0.168)

Adjuvant treatment

EBRT

24

25.5

 

4

22.2

 

3

16.7

 

(0.557)

 

Radiation dose (Gy)

  

48.7 (30–60)

  

50.1 (50.0-50.4)

  

35.8 (30–45)

(0.887)

 

Chemotherapy (total)

15

16.0

 

18

100

 

2

11.1

 

(0.000)

 

Chemotherapy (only platinum derivatives)

5

5.3

 

2

11.1

 

-

-

  
  1. Gives an overview of the performed treatment modalities. The ‘Cetuximab-Taxane Recurrency Scheme’ combines salvage surgery (SS), Brachytherapy (BT) and adjuvant chemoprotocol in regard to previous external radiation (EBRT), previous chemotherapy (CTx). To exhaust chances an external boost was added whenever reasonable. Differences between the study group and the control group were analyzed by *chi-square test and Mann–Whitney U test